This meta-analysis looked at data from 7,810 adults with moderate to severe active Crohn's disease. Researchers compared the effects of the medication ustekinumab against TNF antagonists, which include adalimumab and infliximab. The study specifically looked at extraintestinal manifestations (EIMs), which are symptoms that affect parts of the body outside of the digestive tract.
The findings showed that ustekinumab was associated with a significant reduction in the risk of fatigue and arthritis or arthralgia during maintenance therapy. In contrast, weekly adalimumab treatment was linked to an increased risk of fatigue. The study did not find statistically significant benefits for adalimumab or infliximab regarding most other measured extraintestinal symptoms.
Because this is a meta-analysis of existing trials, the results show a link between these medications and specific symptoms rather than a guaranteed outcome for every patient. While ustekinumab showed potential advantages for managing fatigue and joint pain, individual experiences can vary. Patients should talk to their doctor to determine which treatment plan is best for their specific needs.
